Age Interactions in the Development of Naturally Acquired Immunity to Plasmodium falciparum and Its Clinical Presentation
Open Access
- 31 July 2007
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 4 (7) , e242
- https://doi.org/10.1371/journal.pmed.0040242
Abstract
Naturally acquired malaria immunity has many determinants and, in the absence of immunological markers of protection, studies assessing malaria incidence through clinical endpoints remain an approach to defining immunity acquisition. We investigated the role of age in disease incidence and the effects of chemoprophylaxis on clinical immunity development to Plasmodium falciparum during a randomised controlled trial. A total of 415 Tanzanian infants were randomly assigned to receive weekly malaria prophylaxis with Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone) or placebo between the ages of 2 and 12 mo. Children were followed up until 4 y of age. Uncomplicated febrile malaria, severe malaria, and anaemia morbidity were assessed through hospital-based passive surveillance. Compared with the group of control participants, there was a marked reduction in the incidence of clinical malaria, severe malaria, and anaemia in the group of children who had received chemoprophylaxis during the first year of life. After discontinuing the intervention, there was a significant increase in the incidence of clinical malaria for 2 y. The cumulative rates of clinical malaria, by age 4 y, were slightly higher in the group of children who had previously received chemoprophylaxis: 3.22 episodes versus 3.02 episodes in the group of control participants; rate difference 0.20 (95% confidence interval [CI]: −0.21 to 0.59). By age 4 y, the cumulative rates of severe malaria, however, were slightly lower in chemosuppressed children (0.47 versus 0.59) (rate difference −0.12 [95% CI: −0.27 to 0.03]). The number of episodes of anaemia was also slightly lower in chemosuppressed children by age 4y: 0.93 episodes (95% CI: 0.79 to 0.97) versus 1.12 episodes in the group of control participants (95% CI: 0.97 to 1.28) (rate difference −0.19 [95% CI: −0.40 to 0.01]), respectively. Reducing exposure to P. falciparum antigens through chemoprophylaxis early in life can delay immunity acquisition. Infants appear to acquire immunity faster than older children, but have a higher risk of developing severe forms of malaria and anaemia. These findings provide insight on the interplay between immunity and exposure-reduction interventions.Keywords
This publication has 23 references indexed in Scilit:
- Modeling the Development of Acquired Clinical Immunity to Plasmodium falciparum MalariaInfection and Immunity, 2004
- Innate immunity to malariaNature Reviews Immunology, 2004
- Combating malaria morbidity and mortality by reducing transmissionParasitology Today, 1996
- Will reducing Plasmodium falciparum malaria transmission alter malaria mortality among African chilren?Parasitology Today, 1995
- Mortality and morbidity from malaria after stopping malaria chemoprophylaxisTransactions of the Royal Society of Tropical Medicine and Hygiene, 1995
- A longitudinal study of seroreactivities to Plasmodium falciparum antigens in Nigerian infants during their first year of lifeActa Tropica, 1995
- Host Age as a determinant of naturally acquired immunity to Plasmodium falciparumParasitology Today, 1995
- Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern TanzaniaThe Lancet, 1994
- Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmissionActa Tropica, 1993
- COMPARISON OF TWO STRATEGIES FOR CONTROL OF MALARIA WITHIN A PRIMARY HEALTH CARE PROGRAMME IN THE GAMBIAThe Lancet, 1988